Form 4: Collegium Pharmaceutical Director John Freund Acquires Shares Through Restricted Stock Units

Director John Freund reports acquisition of Collegium Pharmaceutical shares through restricted stock units and indirect holdings.

Summary

• On May 15, 2025, John Gordon Freund, a director of Collegium Pharmaceutical, Inc., acquired 9,791 shares of common stock through restricted stock units (RSUs).
• These RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon continued service.
• Freund also indirectly owns 8,625 shares through Skyline Venture Management V, LLC and 34,788 shares through the John Freund Family Partnership IV, L.P.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reflecting stock transactions by a company insider. The acquisition of shares could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The RSUs will be settled on the vesting date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in beneficial ownership for a director of Collegium Pharmaceutical.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Collegium Pharmaceutical, Director, John Freund, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, SEC Filing